BioNTech Starts Phase 1Trial for Prophylactic Herpes Simplex Virus-2 Vaccine

 

• First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163
• BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine collaboration with the University of Pennsylvania to enter the clinic
• The program is part of BioNTech’s strategy to address diseases with high unmet medical need, as no vaccine has been approved for prevention of genital lesions caused by HSV

https://www.biospace.com/article/releases/biontech-starts-phase-1-clinical-trial-for-prophylactic-herpes-simplex-virus-2-vaccine-candidate-bnt163/